Join
Live feed
·
PRReleasevia Quantisnow
Blackstone Inc. logo

Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Advance Novel and Patient-Friendly Oral Enzyme Replacement Therapy for Pancreatic Insufficiency

ByQuantisnow·Wall Street's wire, on your screen.
BX· Blackstone Inc.
Finance

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BX (Blackstone Inc.) and more on Quantisnow.